[1] | Ciccarelli, A., Daly, A.F. & Beckers, A.The epidemiology of prolactinomas. Pituitary 2005, 8:3-6. |
|
[2] | Shrivastava RK, Arginteanu MS, King WA & Post KD. Giant prolactinomas: clinical management and long-term follow up. Journal of Neurosurgery 2002, 97: 299-306. |
|
[3] | Delgrange, E., Trouillas, J., Maiter, D. et al. Sex-related difference in the growth of prolactinomas: a clinical and proliferation marker study. Journal of Clinical Endocrinology and Metabolism 1997, 82: 2102-2107. |
|
[4] | Corsello SM, Ubertini G, Altomare M, Lovicu RM, Migneco MG, Rota CA & Colosimo C. Giant prolactinomas in men: efficacy of cabergoline treatment. Clinical Endocrinology 2003,58: 662-670. |
|
[5] | Shimon, I., Benbassat, C. & Hadani, M. Effectiveness of long-term cabergoline treatment for giant prolactinoma: study of 12 men. European Journal of Endocrinology 2007, 156: 225-231. |
|
[6] | Davis JR, Sheppard MC, Health DA: Giant invasive prolactinoma: a case report and review of nine further cases. Q J Med 1990, 74:227-238. |
|
[7] | Ciric I, Mikhael M, Stafford T, Lawson L, Garces R: Transsphenoidal microsurgery of pituitary macroadenoma with long-term follow up results. J Neurosurg 1983, 59:395-401. |
|
[8] | Molitch ME. Dopamine resistance of prolactinomas. Pituitary 2003, 6: 19-27. |
|
[9] | Yu, C., Wu, Z. & Gong, J. Combined treatment of invasive giant prolactinomas. Pituitary 2005, 8: 61-65. |
|
[10] | Mindermann T & Wilson CB. Age-related and gender-related occurrence of pituitary adenomas. Clinical Endocrinology 1994, 41: 359-364. |
|
[11] | Etienne Delgrange, Gerald Raverot1, Marie Bex, Pia Burman,Be´ne´ dicte Decoudier, France Devuyst, Ulla Feldt-Rasmussen,Marianne Andersen, Dominique Maiter. Giant prolactinomas in women. European Journal of Endocrinology 2014, 170: 31-38. |
|
[12] | Lundberg PO, Osterman PO &Wide L. Serum prolactin in patients with hypothalamus and pituitary disorders. Journal of Neurosurgery 1981, 55: 194-199. |
|
[13] | Cho EH, Lee SA, Chung JY, Koh EH, Cho YH, Kim JH, Kim CJ, Kim MS:Efficacy and safety of cabergoline as first line treatmentfor invasive giant prolactinoma. J Korean Med Sci 2009, 24:874-878. |
|
[14] | St-Jean, E., Blain, F. & Comtois, R. (1996) High prolactin levels may be missed by immunoradiometric assay in patients with macroprolactinomas. Clinical Endocrinology 1996, 44:305-309. |
|
[15] | Gillam MP, Molitch ME, Lombardi G & Colao A. Advances in the treatment of prolactinomas. Endocrine Review 2006, 27: 485-534. |
|
[16] | Oruckaptan HH, Senmevsim O, Ozcan OE & Ozgen T. Pituitary adenomas: results of 684 surgically treated patients and review of literature. Surgical Neurology 2000, 53: 211-219. |
|
[17] | Melmed, S., Casanueva, F.F., Hoffman, A.R. et al. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology and Metabolism 2001, 96: 273-288. |
|
[18] | Dash, S., Annamalai, A.K., Simpson, H.L. et al. Acute shrinkage of a giant prolactinoma, masquerading as an erosive skull base tumour, with cabergoline. QJM 2013, 106: 85. |
|
[19] | Acharya SV, Gopal RA, Menon PS, Bandgar TR, Shah NS: Giant prolactinoma and effectiveness of medical management. Endocrinol Pract 2010, 16:42-46. |
|
[20] | Saeki N, Nakamura M, Sunami K & Yamaura A. Surgical indication after bromocriptine therapy on giant prolactinomas: effects and limitations of the medical treatment. Endocrine Journal1998, 45: 529-537. |
|
[21] | Leong KS, Foy PM, Swift AC, Atkin SL, Hadden DR &MacFarlane IA. CSF rhinorrhoea following treatment with dopamine agonists for massive invasive prolactinomas. Clinical Endocrinology 2002, 52: 43-49. |
|
[22] | Odin P, Oehlwein C, Storch A, Polzer U, Werner G, Renner R,Shing M, Ludolph A & Schuler P. Efficacy and safety of high-dose cabergoline in Parkinson’s disease. Acta Neurologica Scandinavica 2006, 113: 18-24. |
|
[23] | Pinero A, Marcos-Alberca P & Fortes J. Cabergoline-related severe restrictive mitral regurgitation. New England Journal of Medicine 1997, 337: 581-588. |
|